Phenoxy compounds
Medchemexpress LLC Arn-21934 | 2230854-93-8 | 98.1% | 360.46 | 100 MG
ARN-21934 is a potent, highly selective, and blood-brain barrier (BBB) penetrant inhibitor specifically targeting human topoisomerase II α over β. It inhibits DNA relaxation with an IC50 of 2 μM, making it significantly more potent than the anticancer agent Etoposide. ARN-21934 demonstrates a favorable in vivo pharmacokinetic profile and is considered a promising lead compound for anticancer research.
- High potency and selectivity: Potently and selectively inhibits human topoisomerase II α.
- Blood-brain barrier penetrant: Able to cross the blood-brain barrier.
- Favorable pharmacokinetic profile: Exhibits good clearance values and a half-life of 149 minutes in circulation.
- Anticancer potential: Shows antiproliferation activity against various human cancer cell lines.
Medchemexpress LLC ARN-21934 | 2230854-93-8 | 98.1% | 360.46 | 50 MG
ARN-21934 is a potent, highly selective, and blood-brain barrier (BBB) penetrant inhibitor specifically targeting human topoisomerase IIα over β. It inhibits DNA relaxation with an IC50 of 2 μM, significantly more potent than the anticancer agent Etoposide (IC50=120 μM). The compound demonstrates a favorable in vivo pharmacokinetic profile and shows antiproliferative activity against various human cancer cell lines, making it a promising lead compound for anticancer research.
- Potent and highly selective topoisomerase IIα inhibitor
- Blood-brain barrier penetrant
- Inhibits DNA relaxation with IC50 of 2 μM
- Exhibits antiproliferative activity against human cancer cell lines
- Favorable in vivo pharmacokinetic profile
- Appears as a solid, light yellow to green yellow
- Soluble in DMSO (8.33 mg/mL at 80°C with ultrasonic)
Medchemexpress LLC ARN-21934 | 2230854-93-8 | 98.1% | 360.46 g·mol⁻1 | C21H24N6 | 5 MG
ARN-21934 is a selective small-molecule inhibitor of human topoisomerase IIα with demonstrated blood-brain barrier penetration. It inhibits DNA relaxation activity and is supplied for research use in solid form and as DMSO solutions; molecular data and CAS are provided for compound characterization.
- Selective inhibition of human topoisomerase IIα
- Demonstrated blood-brain barrier penetration
- Supplied as solid and as 10 mM DMSO solutions
- High purity suitable for biochemical and cellular studies
- Molecular formula and weight documented for compound characterization
- Available in multiple pack sizes to support varied study scales
Medchemexpress LLC N4-(4-(dimethylamino)phenyl)-2-(pyridin-4-yl)-5,6,7,8-tetrahydroquinazoline-4,6-diamine | 2230854-93-8 | 98.1% | C21H24N6 | 10MG
ARN-21934 is a selective small-molecule inhibitor of human topoisomerase IIα with reported blood-brain barrier penetration and favorable in vivo pharmacokinetics. It inhibits DNA relaxation (IC50 = 2 μM versus etoposide 120 μM) and is supplied for research use only.
- Selective topoisomerase IIα inhibition (IC50 = 2 μM).
- Reported blood-brain barrier penetration and favorable in vivo profile.
- Molecular formula C21H24N6; molecular weight 360.46 g·mol⁻¹.
- High purity, 98.1%.
- Available as solid (5-100 mg) and 10 mM solution in DMSO (1 mL).
- Intended for laboratory research use; not for human use.
Selleck Chemical LLC Pioglitazone HCl S2046-200mg
Pioglitazone HCl (AD-4833 U-72107E) is an inhibitor of cytochrome P450 (CYP)2C8 and CYP3A4 enzymes Pioglitazone HCl inhibits CYP2C8 CYP3A4 and CYP2C9 with Ki of 1 7 M 11 8 M and 32 1 M respectively Pioglitazone HCl is also a selective peroxisome proliferator-activated receptor-gamma (PPAR ) agonist with EC50 of 0 93 M and 0 99 M for human PPAR and mouse PPAR respectively Pioglitazone HCl inhibits mitochondrial iron uptake lipid peroxidation and subsequent ferroptosis